Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Airmid Inc.

Latest From Airmid Inc.

Bionomics to pursue Kv1.3 leads alone for now as Merck Serono alliance ends

Merck Serono and the Australian firm Bionomics have decided to end a collaborative discovery research programme focusing on novel oral small molecule inhibitors of the Kv1.3 ion channel for multiple sclerosis and other autoimmune disorders.

Dermatology Cancer

Circassia plans Phase III of cat and other allergy vaccines

Specialty UK biotech company Circassia plans to progress its ToleroMune cat allergy vaccine into Phase III in the first half 2012 after the follow-up data from its fourth Phase II trial of the product confirmed significant symptom reductions after one year.

Dermatology Immune Disorders

Deals Shaping the Medical Industry (04/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.

Circassia nurses early assets with PAP-1 rights

Circassia, a speciality biopharmaceutical company developing a new class of T-cell vaccines to treat allergies and combat organ transplant rejection, has acquired worldwide development and commercialisation rights to PAP-1, a novel topical therapy for psoriasis and atopic dermatitis, from the privately held US company Airmid.

Dermatology Immune Disorders
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Airmid Inc.
  • Senior Management
  • George Miljanich, PhD, CEO
    George Chandy, MD, PhD, Dir., Drug Dev.
  • Contact Info
  • Airmid Inc.
    Phone: (650) 368-6983
    600 Castle Hill Rd.
    Redwood City, CA 94061